This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

eBook: Personalized Peptide Vaccines & Therapies

Share this article

Arguably the most exciting emerging treatment in immunotherapy, personalized medicine has provided increasing hope and understanding in targeting different cancers by incorporating genetic and data-driven approaches.

In this latest installment from the TIDES eBook Series, we look at the milestones and challenges encountered by today’s leading researchers in the journey of producing personalized vaccines and therapies, including antigen selection and synthesis, machine-learning and regulatory considerations.

Read or download the report above (or click here).

Features include:

  • The Future of Peptide Vaccines and Personalized Peptide Therapies: This whitepaper provides an overview of peptide cancer and infectious disease vaccines, including development within the industry and regulatory view of personalized medicine concepts.
  • Building Better Personal Cancer Vaccines: We explore how effective anti-tumor immunity in humans has been associated with the presence of T-cells directed at cancer neoantigens, as presented by Dr. Catherine J. Wu, Professor of Medicine at Dana-Farber Cancer Institute.
  • Peptide Neoantigen Cancer vaccines and T Cell Therapy: We look at precision antigen selection carried out with a personalized immune response profiling platform demonstrated by Dr. Daniel deOliveira from Genocea Biosciences at TIDES: Oligonucleotide and Peptide Therapeutics.
  • High throughput GMP neoantigen peptide synthesis brings individualized cancer immunotherapy to a new level: This whitepaper from Gyros Protein Technologies examines the growing demand on GMP peptide synthesis for the production of neoantigen-based cancer therapies and the methods to address it.
  • Personal Neoantigen-Based Cancer Vaccine NEO-PV-01 in the Treatment of Metastatic Cancers: We look at the latest overview of the personalized neoantigen cancer vaccine NEO-PV-01, presented by Dr. Jesse Dong, Vice President, Peptide Chemistry at BioNTech.
  • Neoantigen Peptide Therapies: An Interview with Samantha Zaroff Ph.D, Genscript: Dr. Samantha Zaroff Ph.D of Genscript discusses the use of neoantigens in personalised medicine and the challenges behind producing them.

Read or download the report above (or click here).

Share this article

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Virtual Scientific Forum

02 - 05 Mar 2021
Industry leaders and service providers share cutting-edge content and company expertise across the Oligonucleotide, Peptide, mRNA and Drug Delivery spectrum
Go to site